Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: titanium dioxide; powdered cellulose; magnesium stearate; hypromellose; macrogol 4000; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - noumed clarithromycin clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis.acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae;combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. noumed clarithromycin clarithromycin is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro organisms in the conditions listed below:acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; skin and skin structure infections (eg impetigo); disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. acute otitis media.note:1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of clarithromycin in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; magnesium stearate; lactose; sodium hydroxide; povidone; lactose monohydrate; crospovidone - noumed telmisartan is indicated for: - treatment of hypertension - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; lactose; magnesium stearate; povidone; lactose monohydrate; crospovidone - noumed telmisartan is indicated for - treatment of hypertension - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pregabalin, quantity: 300 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; allura red ac; gelatin; sodium lauryl sulfate - noumed pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. noumed pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pregabalin, quantity: 150 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - noumed pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. noumed pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pregabalin, quantity: 75 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; brilliant blue fcf; purified water; sunset yellow fcf; allura red ac; gelatin; sodium lauryl sulfate - noumed pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. nomed pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pregabalin, quantity: 25 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - noumed pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. noumed pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - donepezil hydrochloride monohydrate, quantity: 10.43 mg (equivalent: donepezil hydrochloride, qty 10 ) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin - treatment of mild, moderate and severe alzheimer's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - donepezil hydrochloride monohydrate, quantity: 5.22 mg (equivalent: donepezil hydrochloride, qty 5 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; lecithin - treatment of mild, moderate and severe alzheimer's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 200 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; maltodextrin; calcium carbonate; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.